Imagine that you are in your sixties or seventies, and on a brisk walk. Your muscles contract, setting off small waves of calcium and other signaling molecules. In response, your skeletal muscle cells secrete a host of myokines into your bloodstream—molecules such as interleukin-6 (IL-6) and irisin. Meanwhile, your adipose tissue, sensing metabolic demands, releases adipokines that fine-tune insulin sensitivity. Your liver, stirred by changes in blood flow and metabolic substrates, sends out hepatokines such as fibroblast growth factor 21 (FGF21). And your bones, subjected to the forces of gravity and muscle tension, secrete osteocalcin or other osteokines that preserve skeletal integrity. Even your brain—through glial cells or neurons—contributes neurokines that bolster synaptic plasticity. All these exerkines then travel through the bloodstream, coordinating with different organs, collectively pushing back against the harmful effects of age-related stress and inflammation.

It is well known that aging coincides with a series of systemic changes—reduced muscle mass (sarcopenia), diminishing bone density (osteoporosis), elevated inflammation (“inflammaging”), and a decline in mitochondrial quality. The danger is that these changes feed into each other, leading to a spiraling loss of vitality. But the exerkines triggered by regular physical activity can break this vicious cycle. For instance, certain exerkines promote a shift away from chronic inflammation by boosting the production of anti-inflammatory mediators like interleukin-10 (IL-10) and restricting pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α). Others enhance the oxidative capacity of skeletal muscle, reducing the accumulation of reactive oxygen species (ROS) and preventing mitochondrial decay—major contributors to cellular dysfunction in older adults.

Scientists have begun to pinpoint precisely how exerkines exert these protective effects. One factor is the well-known molecule IL-6, which can exhibit pro-inflammatory behavior in certain contexts but acts as an anti-inflammatory signal during and immediately after exercise. Another is irisin, a hormone-like factor that helps convert white adipose tissue into a more metabolically active “beige” fat, raising one’s resting energy expenditure while improving insulin sensitivity and metabolic health. Meanwhile, fibroblast growth factor 21 (FGF21), secreted mainly by the liver, exerts beneficial effects on glucose control and lipid metabolism, thus lowering one’s vulnerability to type 2 diabetes. Myostatin, once considered only a negative regulator of muscle growth, has emerged as a possible modulator of tumor suppression. Apelin, another exerkine, fosters the health of both bone and muscle tissue, helping older bodies withstand the rigors of daily life. And in the brain, molecules like clusterin or glycosylphosphatidylinositol-specific phospholipase D1 (GPLD1) can dampen inflammation and shore up neural plasticity, safeguarding cognition in older adults.

At first, it may sound like an astonishing synergy: how can the same physical movement help the heart, bones, muscles, immune system, and even the brain? But the body’s architecture is deeply interconnected, and exerkines serve as the biochemical messengers that tie all these benefits together. Perhaps the clearest example is skeletal muscle, the largest organ by mass in most people, which rapidly communicates with other tissues during a workout. The molecular signals it emits—the myokines—can travel to the liver to promote better fat oxidation, or to the brain to encourage synaptic plasticity. They may also act on the immune cells, fine-tuning the balance between pro-inflammatory and anti-inflammatory signaling. Likewise, adipose tissue secretes adiponectin, which fosters fatty acid oxidation and reduces insulin resistance in muscle and liver, while also modulating inflammatory processes system-wide. This level of cross-organ “conversation” explains why a simple brisk walk or a few sets of resistance exercises per week can lower the risk of so many age-related conditions—from cardiovascular disease and type 2 diabetes to osteoporosis and some cancers.

Given the multiplicity of exerkines, it should be no surprise that different forms of exercise generate distinct benefits. The recommendation for older adults, proposed by various international guidelines, generally includes a combination of resistance training, aerobic exercise, and balance activities. Resistance or weight training stimulates muscle hypertrophy and strength gains, spurring the release of exerkines that specifically promote muscle repair and anabolism. Aerobic exercises like walking, jogging, or cycling, at intensities around 55–70% of maximum heart rate, are associated with improved cardiovascular function, higher levels of beneficial cytokines such as IL-10, and better glycemic control. Balance and flexibility exercises, such as yoga and tai chi, are no less important; they may not generate as high an acute exerkine surge as intense resistance training or cardio, but they do help preserve neuromuscular coordination and reduce the risk of falls—a critical factor in healthy aging.

One of the cornerstones of exerkine research is the notion that improving mitochondrial function is a central mechanism of “exercise as medicine.” With age, mitochondria in cells become less efficient at producing ATP (adenosine triphosphate), and they accumulate oxidative damage. Exercise can mitigate this by increasing the expression of key enzymes like glutathione peroxidase (GPx), superoxide dismutase (SOD), and heme oxygenase-1 (HO-1), which help neutralize free radicals. ROS no longer run rampant, so the negative feedback loop leading to further mitochondrial damage is dampened. Meanwhile, exerkines promote the production of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), a major driver of mitochondrial biogenesis. As a result, older individuals who engage in physical activity can regenerate healthier mitochondria, thus powering their cells more effectively. The payoff is less cellular senescence, improved nutrient sensing, and often a reduction in chronic inflammation.

It is important to note that the synergy between exercise and exerkines extends into domains like cognitive function. Regular training fosters a rise in brain-derived neurotrophic factor (BDNF), a neurotrophin essential for neuronal survival, synaptic plasticity, and hippocampal neurogenesis. This helps guard against the cognitive deficits associated with disorders such as Alzheimer’s disease. Some exerkines, such as glycosylphosphatidylinositol-specific phospholipase D1 (GPLD1) and platelet factor 4 (CXCL4), have also been implicated in hippocampal neurogenesis, encouraging the generation of new neurons and reversing certain aspects of age-related mental decline. These discoveries resonate strongly with observational data showing that physically active older adults frequently show slower cognitive decline and lower incidence of neurodegenerative conditions.

For those concerned about type 2 diabetes, exercise again steps in with an exerkine-mediated strategy. Muscle contraction not only draws glucose into cells via transporters like GLUT4, it also triggers the release of certain hepatokines from the liver and adipokines from fat that normalize blood sugar levels. FGF21, for instance, fosters insulin sensitivity, while HSP72 (heat shock protein 72) can prevent misfolded protein accumulation in pancreatic beta cells. Even short bursts of activity can drive these beneficial changes. Though many older people worry about whether they can safely engage in vigorous workouts, the research points to moderate, consistent habits—like walking daily or lifting light weights multiple times a week—as enough to catalyze these systemic benefits.

Another striking area of discovery is the way exerkines appear to influence bone health. Osteocalcin, produced by bone in response to the mechanical load from weight-bearing exercise, helps maintain bone mineral density and appears to have metabolic functions that extend beyond bone. It may, for example, improve insulin sensitivity. Meanwhile, molecules such as TGF-β1 and apelin, also upregulated by exercise, can help coordinate bone formation and muscle mass. For older adults whose bones grow increasingly fragile, these factors are a ticket to reduced fracture risk and better musculoskeletal resilience. In some scenarios, the synergy between osteokines and myokines can help accelerate bone healing after injury or surgery, a tremendous boon for those in advanced age.

Add to this the remarkable possibility that exerkines carry at least some anti-cancer properties, and exercise’s significance in health management gains still more luster. Myostatin, ironically known for suppressing muscle growth, has recently been linked to anti-tumor functions in certain tissues, possibly by dampening pathways that drive unchecked proliferation. Irisin, once studied for its effect on adipose tissue browning, also shows promise as an anti-tumor agent in preclinical models, often by boosting the immune system’s detection of malignant cells or by altering local inflammatory signals that help tumors thrive. Even though these studies are preliminary, they open an exciting dimension of research: perhaps a consistent exercise routine could lower both the risk of developing cancer and, in some cases, slow progression for those who already have it.

Despite the avalanche of positive evidence, we must tread carefully. Not all forms or intensities of exercise deliver uniform exerkine responses. Overtraining—exercising too vigorously or too frequently—can create oxidative stress or immune suppression, especially in older individuals who may have other comorbidities. The goal, therefore, is moderation and personalization: designing a plan that taps into the beneficial exerkine output without overwhelming the body’s capacity to recover. Many new areas of research revolve around “exercise mimetics,” compounds that mimic the effect of exerkines by targeting the same molecular pathways. For individuals too frail to exercise adequately, such compounds could theoretically provide the health benefits of a workout. But the nuance is that exercise is not merely a pill to be replaced; it sets in motion large-scale mechanical, neural, and metabolic processes that may not be fully replicated by a single compound or cocktail.

What will the future hold for this intriguing domain of exerkines and anti-aging strategies? One possibility is that health practitioners will monitor exerkine levels in the bloodstream to gauge whether an older adult’s exercise regimen is truly effective. Another is that gene- or cell-based therapies could selectively increase expression of beneficial exerkines, or block “rogue” molecules that hamper healthy aging. As more is uncovered about how these molecules act and interact, a new generation of geriatric medicine could arise, leveraging exerkines to combat conditions as diverse as Alzheimer’s, frailty, and diabetes. Pharmacologists already see exerkines as potential “druggable” targets. For instance, if we can harness the browning effect of irisin safely, we might treat obesity without radical changes in diet. If we can modulate clusterin or BDNF effectively, we might slow cognitive decline. Conversely, controlling overactive inflammatory exerkines in certain autoimmune settings might stave off age-associated autoimmune conditions.

Yet, in the midst of all these futuristic innovations, the core message remains clear: regular movement, even in modest doses, is already our best bet for “turning on” these beneficial exerkines. Where certain pharmaceutical avenues may take years to become safe and widely available, everyday exercise is accessible now, with little risk and abundant upside. Medical experts emphasize that older adults should combine strategies: build in some resistance training to preserve muscle mass and bone density, incorporate aerobic exercise to bolster cardiovascular and metabolic function, and do balance activities to reduce fall risk and maintain neural reflexes. These are not complicated tasks, but the molecular payoffs—in the form of exerkine release—can be profound.

Ultimately, the story of exercise-induced exerkines is one of the most compelling examples of how our bodies are designed for movement, and how that movement orchestrates a symphony of positive biological signals. By activating these signals through conscious, consistent activity, we tap into a powerful, evolution-built mechanism that defends us against the degradations of time. Gone are the days when we could think of exercise merely as a means to burn calories. Instead, each session of walking, resistance training, or mindful balance exercises sets off thousands of molecular changes that can be harnessed to keep us healthier for longer. It is a powerful illustration that our biology wants us to move, and in moving, we coax our cells to produce molecules that can keep the ravages of age at bay.

As researchers continue to refine our understanding, we may see more targeted advice on the most effective exercise “doses,” frequencies, and intensities for stimulating beneficial exerkines. We may also see novel interventions that help older adults overcome barriers to physical activity, from wearable technology that tracks functional movement patterns to community programs aimed at delivering personalized exercise regimens. If further breakthroughs arrive with safe and effective exercise mimetics, so much the better. Yet for now, the basic science underscores a unifying conclusion: exercise remains one of our most potent forms of preventive medicine, not just for the muscle and cardiovascular advantages, but for the invisible molecular crosstalk that might very well determine how gracefully and how long we age.

Subject of Research: Exercise and Exerkines in Anti-Aging and Disease Prevention
Article Title : Exercise and Exerkines: Mechanisms and Roles in Anti-Aging and Disease Prevention
News Publication Date : February 2025
Article Doi References : https://doi.org/10.1016/j.exger.2025.112685
Keywords : Exerkines, Anti-aging, Exercise Physiology, Mitochondrial Function, Muscle Mass, Inflammaging, Cognitive Decline, Metabolic Homeostasis, Bone Density

The story begins, rather simply, with individuals such as Seattle-based physician Naomi Busch. As the only doctor in her book club, she found herself bombarded by questions about the so-called “hallmark” menopause experiences—hot flushes, unpredictable mood swings, stubborn insomnia. Although these are well-documented changes, Busch realized she was ill-prepared to provide answers that extended beyond what a quick Internet search might yield. Menopause, it turned out, was not part of the typical medical-school syllabus, at least not in any robust manner. When she tried referring her acquaintances to local experts, she found such specialists were often booked up for months, leaving these women in limbo, forced to soldier through hot flushes, irregular cycles, and unsettled mental states with little more than a shrug from their regular providers.

Motivated to fill this knowledge gap, Busch immersed herself in continuing education, ultimately passing a competency exam to become a certified practitioner through The Menopause Society, which is based in Pepper Pike, Ohio. In 2024, more than 1,300 practitioners followed a similar path—an astonishing rise from prior years, underscoring a mounting curiosity to revisit menopause in fresh, evidence-based ways. The UK-based International Menopause Society has also seen a surge, with more than 2,600 people completing its free online training program in 2024 compared to fewer than 2,000 the prior year. This phenomenon suggests that medical education might soon catch up with the reality that an ever-growing percentage of the population, both in high-income and developing nations, need specialized care for the menopausal transition.

In parallel with this surge in professional interest, the cultural conversation around menopause is evolving. Beyond the classic symptoms that prompt day-to-day discomfort—hot flushes, night sweats, brain fog—there are heightened risks of chronic health conditions such as cardiovascular disease, osteoporosis, and type 2 diabetes. Additionally, researchers note potential risks to neurological health and cognitive functioning. These are not minor side concerns: a woman (or transgender, non-binary, or intersex person who undergoes a similar transition) might be at the height of a career or still raising children, yet finds themselves coping with unpredictable episodes of insomnia, confusion, or palpitations. If health-care providers are poorly prepared to help, this stage of life can become deeply isolating.

Typical advice to those in midlife—perhaps an oral contraceptive if still perimenopausal and seeking to avoid a surprise pregnancy—might help modulate hormones to a certain extent, but can also bring risks of blood clots or insufficiently address the full slate of symptoms. Some might attempt a patchwork approach: non-hormonal medication for hot flushes, antidepressants, behavioral therapies, or acupuncture for mood. But many remain dissatisfied, feeling these methods barely dent the life-altering realities of menopause.

For a long time, hormone replacement therapy (HRT)—or, increasingly, “menopausal hormone therapy”—was the gold standard for easing symptoms. In the eyes of many older physicians, it was once so routine as to be unremarkable. Then, in 2002, the large Women’s Health Initiative (WHI) study published an alarming early report (1) linking combined oral oestrogen and progestin therapy to a heightened risk of breast cancer, stroke, and heart attacks. Immediately, prescriptions for hormone therapy plummeted around the globe. Women in the United States, for example, who had previously been on or considering hormone therapy reacted to the headline that “HRT is unsafe,” and usage dropped from roughly 40% to below 5%. Countries worldwide witnessed similarly precipitous declines.

In subsequent years, however, deeper data analysis from that same WHI study and more modern investigations has revealed a more nuanced picture. Timing seems crucial. When hormone therapy is initiated years after menopause has already ended, it might indeed exacerbate heart disease and bring certain risks. Yet for those who begin therapy earlier—close to the onset of menopause—evidence now points to potential benefits, such as reduced risk for fractures, possible cardioprotection, and less cognitive decline. Additionally, the formulations of hormones have changed drastically since 2002: lower doses, different routes of delivery (especially transdermal patches), and “body-identical” hormones have gained prominence, minimizing some of the risks that were associated with older methods. A major re-analysis (2) published in May 2024 reaffirmed that the original study did not reflect current best-practices, yet a swirl of misconceptions has lingered in the public mind and even in some scientific communities.

Meanwhile, the conversation has grown more sophisticated. Modern hormone therapy does not consist solely of adjusting oestrogen and progesterone levels; contemporary researchers are investigating whether testosterone might protect against bone density loss in the menopausal population. Others are examining how to best mitigate vascular risks in women who may already be predisposed to conditions such as hypertension or atherosclerosis. Some data even point to a possibility that well-timed hormone therapy could reduce the incidence of dementia or memory decline, though these findings remain preliminary. Skeptics, however, caution that it is easy to over-interpret observational data. To truly confirm these hypotheses, randomized controlled trials must be carefully designed and implemented.

While refining hormone therapy is one path, there is an altogether different line of research attempting to forestall menopause itself. The reasoning goes like this: ovaries do more than produce the well-known reproductive hormones. They coordinate a complex network of signaling molecules, beneficial compounds, and cyclical processes throughout the body. If the ovaries age prematurely or fail, that can trigger a cascade of chronic health conditions. By delaying or slowing ovarian aging, some scientists hope to prolong the period when these hormonal benefits naturally persist.

Among the researchers tackling this idea is Zev Williams at Columbia University in New York. One method involves drugs such as rapamycin, already used for immunosuppression in organ transplant recipients but found in animal models to prolong ovarian function in mice (4). In principle, if rapamycin can slow the depletion of egg-containing follicles in humans, it might postpone the menopausal transition by up to seven years or more. That is a remarkable idea, but also one that must be tested rigorously. Williams and his colleagues are in the midst of a prospective, randomized, double-blind trial with about 50 healthy women between the ages of 35 and 45, who will either take rapamycin or a placebo for 12 weeks. The research community remains cautious, as rapamycin is already popular in anti-aging circles, and premature use without strong data can lead to unforeseen complications.

Another intriguing technique involves surgically removing small sections of ovarian tissue in a woman’s younger years, freezing that tissue, and reimplanting it later, perhaps well into midlife. This approach has already been used successfully for younger cancer patients who must undergo chemotherapy; reintroducing ovarian tissue years later can restore fertility. Could the same concept help healthy women to “pause” their ovarian clock, effectively forestalling menopause? Simulations by reproductive specialists, including Kutluk Oktay at Yale University, suggest this tissue reimplantation might yield a delay of several years or more (5). If started early enough, repeated transplants might even stave off menopause indefinitely. That possibility is both alluring and fraught with ethical and practical implications. Indeed, no guidelines exist for reimplanting cryopreserved tissue in completely healthy individuals. Many clinicians point out that there could be uncharted risks to removing slices of a functioning ovary, including potential to trigger earlier menopause if something goes awry.

However it ultimately plays out, the possibility that researchers might one day “control” menopause is not science fiction. The US National Institutes of Health, for instance, held a round table on menopause research in May 2024 to chart priorities. Meanwhile, the White House Initiative—established during the administration of Joe Biden—directed $113 million specifically for women’s health research. Moreover, ARPA-H (Advanced Research Projects Agency for Health) is orchestrating some of these new investigatory thrusts, with the aspiration to accelerate game-changing biotech solutions. Menopause is increasingly viewed as a domain ripe for breakthroughs, simply because it affects so many people at a time of life when they often hold major responsibilities—professional and personal alike.

Of course, any sophisticated therapy for menopause, be it hormone-based or reliant on preserving ovarian function, is only as good as the clinicians delivering it. Yet today’s doctors, especially in general medicine, are often undertrained in menopause management. A 2023 survey (6) indicates that roughly 31% of obstetrics and gynecology residency programs in the United States admit they dedicate insufficient formal time to the subject. That leaves many front-line physicians either inadvertently reinforcing the outdated notion that “this is just something you must bear,” or resorting to incomplete solutions for patients. Busch’s anecdote in Seattle resonates: there is a wide gap between evidence-based best practices and what average patients hear in clinical settings.

One reason for that gap is the lingering fear from 2002—some older physicians are still reluctant to mention hormone therapy because they themselves internalized the message that it was harmful. Younger physicians, on the other hand, might have grown up in a climate where menopause care is rarely discussed. A few experts, including Mayo Clinic’s Stephanie Faubion and Harvard’s JoAnn Manson, are tirelessly trying to correct the public record on hormone therapy. They emphasize that the “window of initiation” matters: it is probably safer and more beneficial to start hormone therapy within a decade of menopause or before age 60, so long as no contraindications exist. Doing so, they say, may reduce the risk of osteoporosis, help with heart health, and mitigate the symptoms that can compromise quality of life. Over time, the medical field might see a return to routine hormone therapy as a meaningful intervention for many. But they also caution that it is not for everyone; risk factors, lifestyle, personal preferences, and comorbid conditions all shape whether hormone therapy is advisable.

Meanwhile, other intriguing fronts are opening up in the realm of gut microbiome research. Observations linking gut flora to shifting levels of female sex hormones suggest that targeted interventions—probiotics, carefully tuned diets, or other ways to nudge the microbiome—could help manage weight gain, mood, or bone health. And because female hormones are tightly tied to circadian rhythms, researchers including Julie Pendergast at the University of Kentucky are exploring whether restricting food intake to certain times of day or optimizing one’s light exposure might buffer some of menopause’s metabolic challenges. By pulling these levers, scientists may find new ways to ease transitions for people who are highly symptomatic.

Yet all these breakthroughs, from hormone reformulations to extended ovarian life, will mean little if only a small fraction of the population can access or trust them. Socioeconomic disparities already plague women’s health. Surveys show that non-white women tend to have more severe menopausal symptoms yet are less likely to receive hormones, for reasons that include systemic barriers and historical distrust. This disparity intensifies the urgency of forging policy changes that ensure equitable access to the next generation of menopause treatments. Similarly, cost remains a looming factor. Although rapamycin, for instance, is relatively inexpensive, repeated cryopreservation surgeries or real-time hormone monitoring devices might not be. If the objective is to improve public health on a large scale, the success of any solution will hinge on whether it can be delivered affordably and ethically.

Then there is the matter of who is included in the conversation: the push to mainstream menopause care must also take into account transgender, non-binary, and intersex people, who can undergo a menopause-like transition if they have ovaries. Studies seldom address these groups in detail, compounding their struggle to find specialized care. If a wave of education for providers does come to fruition, it must incorporate these diverse experiences, ensuring that everyone can reap the benefits of new scientific insights.

Naomi Busch, for her part, exemplifies a new breed of physician taking up the banner for menopause care. She left her old model of primary-care practice to open Seattle Menopause Medicine. About 400 patients now rely on her for deeper, more individualized discussions of hormone therapy, symptom management, and overall well-being. She mentions that most are middle-class and a majority are white, reflecting broader access inequities. Busch hopes to counter that by offering group classes, working with family-practice residents, and participating in local programs that expand access. Nonetheless, it is a constant struggle to ensure that all who need these resources can receive them in a timely manner. Some activists call for government policy that directly invests in menopause education for medical students and general practitioners, so that no future patient is told “Well, that’s just menopause,” with a dismissive shrug.

Bubbling beneath all of this is a sense of real excitement among researchers. Many see menopause as a puzzle that stands at the crossroads of reproductive biology, endocrinology, neurology, and aging. If the puzzle is cracked—if we can safely modulate or even delay the onset of menopause, or tailor hormone regimens perfectly—then the broader payoffs could be enormous. Fewer fractures mean a significant reduction in medical costs and improved quality of life. Better cardiovascular outcomes imply fewer hospitalizations for heart disease, a leading cause of death in postmenopausal women. And if cognition and mood remain more stable, that supports workplace productivity, personal relationships, and mental health.

Perhaps that is why advocates ranging from Hollywood celebrities such as Halle Berry to local activism groups have become so vocal. Berry’s support of US legislation that would bolster menopause research and the formation of various grassroots campaigns in the UK and other regions underscore that it is not just a “hot flash” in the scientific literature; it is a cultural shift. Women (and others who experience menopause) are increasingly speaking openly about symptoms that were once private hush-hush matters, thereby validating the experiences of half the population. In some sense, society is rejecting the old norm that menopause is merely an invisible endpoint of reproductive life that must be endured in silence.

Still, many complexities await resolution. For instance, the exact interplay between hormone therapy and cancer risk demands more careful scrutiny. Even with lower-dose formulations, certain populations might face slightly elevated risks. Meanwhile, more data on diversity—variations in genetics, ethnicity, comorbidities—are essential to develop truly personalized recommendations. Studying the best possible interventions for bones, hearts, brains, and emotional stability will require extensive, long-term cohort studies. The White House Initiative’s $113 million infusion is just an initial step. Critics note that it is dwarfed by the overall health-research budget and that more targeted funds must be allocated to see real transformation. Yet, for the first time in decades, one sees genuine alignment among government agencies, private foundations, and the public.

Busch, having confronted these uncertainties head-on, often tells her patients that menopause management is still more of an art than a perfect science. Hormone therapy itself “is not one-size-fits-all,” she says, adding that her role is to explain the potential risks and benefits to each person, factoring in family history, personal predispositions, and tolerance for side effects. She encourages early conversation: do not wait until years of suffering have gone by. If a woman in her late 40s starts to notice disruptive cycles or dramatic hot flushes, it might be exactly the right time to explore treatment that fits her lifestyle. Conversely, some want to avoid exogenous hormones altogether, either out of caution or personal preference, and might find partial relief through lifestyle adjustments, mindfulness, or non-hormonal interventions such as fezolinetant or elinzanetant.

The broader transformation, though, is not merely about a menu of pharmaceutical choices. It is also about reframing the conversation so menopause feels less like a dreaded breakdown and more like a natural, though complicated, transition—one that can be navigated with science on one’s side. Let it be said: there is a distinct mood among experts that we are entering a “new science of menopause” era, where old prejudices against hormone therapy are countered by fresh, data-driven arguments for targeted usage. Meanwhile, radical lines of inquiry—extending ovarian longevity, developing real-time hormone sensors, or even regenerating functional tissue—promise to continue capturing headlines.

The scale and impact could be enormous: at the population level, lessening the burdens of menopause could potentially help keep more people in the workforce, reduce healthcare expenditures on advanced osteoporosis or heart disease, and enhance family dynamics by ensuring a more stable midlife. Specialists emphasize that extended ovarian function is not about pandering to a youth-obsessed culture, but rather about healthy aging and giving individuals the fullest possible quality of life. If, one day, someone can choose to preserve their reproductive system and hormones far into their fifties or sixties without unacceptable risk, that might be as revolutionary as the introduction of the birth-control pill was for earlier generations.

For now, we remain in a transitional phase. Doctors such as Busch are bridging the knowledge chasm by getting certified in menopause management, but there remain countless regions where no specialized providers exist, leaving people to search online for answers or rely on guesswork. Medical schools are slowly recognizing that training in menopause should be fundamental, not optional. From a research standpoint, newly established training programs, collaborations, and dedicated NIH or ARPA-H grants could rapidly expand the ranks of investigators delving into ovarian biology, endocrine function, and the intricacies of menopause. Ultimately, the measure of success will be how well this emerging science translates into tangible help—whether that means developing sophisticated hormone patches that adapt to daily fluctuations, or launching powerful public-health campaigns that remove the stigma of what is, in effect, a universal life transition.

The potential payoff is as vast as it is overdue. At a time in history when we can decode genomes, regenerate tissues, and create advanced vaccines in record time, it is perhaps remarkable that half the population’s fundamental biological transition has remained, for so long, an afterthought in mainstream science. Now, the tide is turning, driven by a potent mix of patient advocacy, scientific breakthroughs, and political support. It is not hyperbole to suggest that if we get menopause research right—if we can offer real relief and improved health outcomes to millions around the world—the result might be one of the most transformative developments in women’s health in a generation.

Subject of Research: The evolving science of menopause and emerging therapies
Article Title : The New Science of Menopause: These Emerging Therapies Could Change Women’s Health
News Publication Date : 22 January 2025
Article Doi References : https://doi.org/10.1038/d41586-025-00069-4
Image Credits : Scienmag
Keywords : Menopause, Hormone Therapy, Ovarian Function, Women’s Health, Bone Density, Rapamycin

To appreciate this story, we first need to understand the significance of cellular senescence, a state in which cells exit the cell cycle and remain in a type of permanent arrest. Senescent cells, or SnCs as they are sometimes abbreviated, accumulate with age, building up across tissues and secreting a pro-inflammatory set of factors known as the senescence-associated secretory phenotype. The common wisdom in biology has been that cellular senescence serves as a protective stop sign for damaged or stressed cells, preventing them from turning cancerous. However, as these SnCs collect in older tissues, their presence sparks chronic inflammation, tissue dysfunction, and a range of detrimental effects associated with aging. The standard approaches to mitigate their impact often rely on purging them from the body (the senolytic method) or suppressing their inflammatory signals (the senomorphic method). Both strategies bring their own set of complications, prompting the pursuit of alternate solutions, ones that might rescue SnCs and coax them back into a functional state.

This is where exosomal miR-302b steps into the limelight. Exosomes are minuscule vesicles, typically 30 to 150 nanometers in diameter, that bud off from the membranes of cells. Human embryonic stem cell-derived exosomes, known in the study as hESC-Exos, contain a wealth of proteins, nucleic acids, and microRNAs, each capable of influencing fundamental processes like growth, repair, and inflammation. Among the most prevalent cargo items discovered in hESC-Exos was a particular microRNA named miR-302b. MicroRNAs can bind to specific messenger RNAs within cells, reducing their expression. In the case of miR-302b, it appears to target two major regulators of cell cycle arrest: Cdkn1a and Ccng2. By dampening these regulators, miR-302b seemingly releases senescent cells from their stagnant condition, restoring the proliferative capacity once thought to be irreversibly lost. The idea that we can restore old or stressed cells to a more youthful state, rather than simply killing them off, is as enthralling as it is unexpected.

During in vitro experiments, hESC-Exos were administered to senescent human fibroblast cells. These fibroblasts, known as IMR-90, had undergone the typical trajectory of aging, culminating in what is termed replicative senescence. After exposure to the purified exosomes for 72 hours, the cells displayed a marked decline in well-established senescence markers, such as SA-β-gal activity and high levels of p21 and p16. More strikingly, these rejuvenated cells began proliferating again, suggesting that the exosomes had reversed their once-stable proliferative arrest. To confirm that miR-302b was the key factor, tests were performed with direct miR-302b overexpression. This intervention was sufficient to reproduce the same anti-senescence effects, effectively exonerating other molecules in hESC-Exos from prime responsibility. It was in these momentous observations that the notion of “Senoreverse” took shape, pointing to a strategy that can do far more than moderate senescence; it can apparently make it yield to renewed vigor.

Beyond cell culture dishes, the study investigated what might happen if older mice were dosed regularly with hESC-Exos or with exosomes loaded explicitly with miR-302b. To begin with, the scientists wanted to confirm that such exosomes were not tumorigenic. After all, hESC-Exos originate from cells that are part of the embryonic blueprint, raising concerns about their capacity to unleash unfettered cell division. Reassuringly, mice that were injected systematically with these exosomes over multiple months failed to present heightened rates of tumors or other severe complications. This safety check paved the way for a longevity analysis to be undertaken with the exosome or miR-302b therapy. The results were dramatic: mice that received hESC-Exos displayed extended survival, with both the median and maximum lifespans surpassing those of their untreated peers. From a morphological standpoint, the animals on therapy appeared younger, exhibiting healthier fur, improved muscle strength, superior coordination, and reduced chronic inflammatory markers. At a cellular level, analysis of multiple tissues (kidney, liver, lung, spleen, and skin) showed diminished senescence signals, reduced expression of p21 and other senescence-related genes, plus an encouraging rise in cells in the S-phase of the cell cycle. The body’s tissue landscapes, typically beleaguered by the ravages of aging, took on a renewed vibrancy, hinting that the therapy did more than just remove a handful of problem cells. Rather, it coaxed them back to function.

Subsequent single-cell RNA-seq data underscored these findings. Senescent cells in the livers and skin of older mice treated with hESC-Exos or miR-302b underwent remarkable transcriptomic shifts, pushing them away from a senescent profile and toward an intermediate or rejuvenated one. Genes involved in the G1/S checkpoint, S-phase progression, or G2/M transition were upregulated, whereas those that force cells out of the cell cycle, like Cdkn1a and Ccng2, were suppressed. The repeated emphasis on these two checkpoint genes suggested they are not mere bystanders but central to controlling the onset and maintenance of senescence. It is as though the exogenous miR-302b floods the regulatory system and seizes these gatekeeper checkpoints, flinging the door wide open for a quiet cell to rejoin the dance of proliferation.

In a further step, the team used an advanced technique called Ago2 Clip-seq, capturing the RNAs bound to Argonaute 2, the main effector of microRNA-mediated silencing. This method validated that miR-302b directly interacts with the 3′ untranslated regions of Cdkn1a and Ccng2 transcripts, dampening their expression. Interestingly, a wide swath of other potential gene targets also surfaced in Clip-seq results. In general, these were skewed toward cell cycle reactivation, DNA repair, or anti-aging pathways, raising the possibility that miR-302b is orchestrating a broad pro-proliferation and pro-rejuvenation cascade. The four to five more intensively validated target genes, though, appear to be the fulcrum.

One might pause to ask: if older mice can spontaneously re-emerge with stronger muscle function, sharper cognition, and more robust tissues, might that not come at a cost, such as igniting rampant tumorigenesis or interfering with processes that keep cells in check? After all, the presence of senescent cells is typically portrayed as a cancer-suppressive mechanism, halting any runaway proliferation in cells harboring DNA damage or oncogenic mutations. The investigators specifically tested that concern by carefully analyzing any potential tumor burdens over the course of up to 24 months of repeated therapy. The result? No surge in tumors or disease burden emerged in animals receiving the exosomes or miR-302b. Indeed, the cause-of-death distribution was statistically indistinguishable from that in the untreated, aging controls. This outcome implies that the reactivation of older cells into proliferation can be carefully orchestrated without unleashing cancer, though extended or new contexts might still reveal complexities. Additional research is needed to verify these findings in diverse genetic backgrounds and in animals predisposed to certain cancers, ensuring that the approach is as safe as these initial results suggest.

Of course, a puzzle remains: how might reactivated cells in aging tissues maintain genomic integrity? Typically, a major impetus behind senescence is the presence of telomere attrition, DNA double-strand breaks, or other forms of genomic instability. When cells break free from senescence, they might risk replicating damaged DNA. Yet the current analysis discovered an uptick in H3K9me3, a marker associated with chromatin stability, and a reduction in γ-H2AX, an indicator of active DNA damage response, in older tissues treated with exosomes or miR-302b. The data raise the speculation that reactivated cells might also heighten their DNA repair pathways, possibly aided by factors inside the exosomes. Indeed, exosomes from hESCs are known to hold a variety of pro-regenerative molecules, so the synergy might well be broader than the single microRNA. Because the investigators singled out miR-302b as the prime agent, it is possible that its manipulation fosters a more stable re-entry to the cell cycle by synchronizing the reduction in DNA damage signals with the upregulation of replication competence.

Another intriguing angle is the interplay between reactivated SnCs and the immune system. Under normal conditions, senescent cells, through their SASP, help recruit immune cells to clear them away. Chronic inflammation arises if the immune system fails to keep pace, leaving SnCs to accumulate and degrade tissue function. If reactivated SnCs produce fewer inflammatory signals and reacquire a more youthful functional state, then we might imagine that SASP-driven persistent inflammation subsides, enabling tissues to run more smoothly, with less infiltration of immune elements. That is consistent with the observation of decreased inflammatory markers in the circulation of older mice receiving exosomal miR-302b. This scenario diverges from common senolytic or senomorphic treatments that either kill SnCs or muzzle the SASP, possibly interfering with beneficial immune surveillance. The newly proposed approach spares these cells from destruction, effectively staves off their inflammatory secretions by letting them rejoin the workforce of dividing cells, and so might neatly evade the pitfalls of other therapies.

Translating these results into any kind of future therapy for humans requires a great deal of caution and more specialized knowledge. The embryonic origin of hESC-Exos can spark ethical debates or safety concerns. The authors addressed tumorigenicity in mice, but the immunocompatibility or potential for immune responses in humans remain uncertain. Similarly, for large-scale production, repeated injections, and quality control, many standardization challenges loom. The direct usage of exosomes from embryonic stem cells might be further complicated by regulatory or ethical constraints. For these reasons, the scientists delved deeper, concluding that the essential factor was miR-302b, something that can be synthesized or carried by more easily standardized exosome carriers or even lipid nanoparticles. Indeed, in the latter part of the research, the authors used 293F cells to produce exosomes that were then loaded via electroporation with synthetic miR-302b. Administration of these prepared exosomes produced the same broad rejuvenation results as seen with hESC-Exos, culminating in older animals living longer, healthier lives. This shift into an off-the-shelf approach for delivering a single microRNA stands as a strong impetus for further investigations aimed at bridging preclinical success to clinical trials.

On a broader scale, we see the concept of “Senoreverse” emerging, with its powerful notion of reversing, rather than eliminating, senescent cells. This story resonates with the grand puzzle in aging research: is it possible to systematically reprogram or modulate all older cells to function as they once did, perhaps bridging the gap between the old and the young at an organismal level? The data here answer with a rousing, if preliminary, yes, though caveats remain. The tested mice exhibited improvements reminiscent of the leap from a geriatric stage to an extended middle age, but not an indefinite suspension of aging. Even the name Senoreverse conjures a sense that we can spin the arrow of time backwards for cells, though no approach can fully disregard the finite nature of biology. The authors address that an indefinite extension of the natural lifespan is not the conclusion to be drawn here. Instead, the therapy slowed or partly reversed the pathological aspects of senescence, enabling a more extended period of healthy living, as well as some improvement in typical markers of youthfulness.

The question of how well these mice might be protected against new triggers of senescence, be it irradiation or toxins, is also relevant. The capacity to reacquire cell division might ironically invite vulnerabilities if DNA repair capacity is insufficient. The authors found that, thus far, no additional disease burden arose in the long term, yet they note that further assessment in tumor-prone models or more genetically diverse backgrounds is a necessity. We might also wonder whether continued indefinite use of such therapy might cause more subtle tissue-level anomalies, or if a narrower window of partial rejuvenation might be safer. The nuance is that a molecule freeing cells from senescence has the potential to unlock a powerful regenerative force or stir some risk-laden beast inside.

Nevertheless, the reliability of the results stands out, especially with scRNA-seq of the liver and skin in older animals. The transcriptomes show that a previously tiny fraction of dividing cells has expanded under therapy, reshaping the tissue’s cellular identity. Simultaneously, the cluster of heavily senescent cells shrinks. The mechanistic synergy behind this shift is no doubt a mixture of direct changes to SnCs and indirect modifications in the environment, such as reduced proinflammatory cytokines. In synergy, the renewed SnCs might produce signals that further encourage healthy cells to proliferate or differentiate appropriately.

Such synergy is reminiscent of embryonic influences. Indeed, the authors note that hESC-Exos have a wide variety of beneficial cargo, from RNA-binding proteins to other microRNAs, any of which might cooperate with miR-302b to sustain these reprogramming or reactivation events. The exosomes could conceivably deliver more than just one beneficial microRNA, which might fortify the reacquired proliferation with improved genome stability. For now, the authors confirm that the presence of miR-302b alone is sufficient to account for the rejuvenation in multiple cell culture and in vivo contexts, although further lines of inquiry might isolate other small RNAs or proteins that amplify or refine the effect.

Another highlight from these data is the improved cognition and physical performance in aged mice. Memory and learning tasks in older rodents typically degrade with time, reflecting hippocampal deficits, synapse decline, or generally heightened neuroinflammation. That older mice receiving exosomal therapy or miR-302b performed better in the Morris water maze (a test of spatial learning and memory) or on the rotarod (a measure of motor coordination) underscores how far-reaching the therapy’s benefits appear to be. The enhanced performance suggests that some neurons or glia implicated in the aging brain might also have partially reversed their senescence or at least had inflammatory stresses alleviated. The fact that these exosomes (or miR-302b cargo) cross or circumvent the blood-brain barrier is a complicated matter that warrants deeper investigation. Possibly, changes in peripheral tissues and systemic inflammation suffice to improve brain function, or there might be a more direct effect within neural tissue.

All of this underscores that the significance of these findings is wide-ranging, beyond a simple demonstration that one can forcibly reintroduce old fibroblasts to the cell cycle. Reversing senescence might resonate across various tissues and organ systems, leading to a globally rejuvenated organism. That no major safety concerns arose in mice up to 24 months of therapy is vital for acceptance, though one must keep in mind that mouse models are not always predictive of human complexities. The way forward, presumably, includes refining dosing strategies, thoroughly verifying the long-term genomic and functional integrity of reactivated cells, and investigating potential synergy or conflict with other rejuvenation strategies, such as partial reprogramming or senolytics. The interplay of cell cycle reactivation and immune regulation might also be studied in detail.

In sum, the revelation that exosomal miR-302b delivered to older mice reversed the hallmark signals of senescence and allowed for renewed proliferation is nothing short of remarkable. The synergy of molecular control—especially the suppression of Cdkn1a and Ccng2—unlocks the gate to cell division once more. Observers might well compare this to opening a second act for cells, one in which they are no longer inert bystanders but active contributors to the body’s rejuvenation. The gains in muscle strength, hair regeneration, improved cognition, and extended lifespan all paint a picture of an approach that challenges the inevitability of the slow, inexorable shutdown in older tissues. And the authors emphasize that applying the approach over long intervals did not provoke an unrestrained cell growth or major diseases, underscoring a potential advantage of reactivating SnCs rather than simply eliminating them. That is not to say the approach is free of unanswered questions: possible interactions with tumors, the stability of repeatedly reactivated cells, and the complexities of large-scale production and regulatory acceptance remain. Yet for now, the story stands as an inspiring, viral-level revelation, appealing to both scientific curiosity and public imagination. The phenomenon captured in this study amplifies a deep human desire—achieving an extended youth or at least a more active, fulfilling elder stage. If this approach is further validated, the method could represent a leap in the quest to mitigate the burdens of aging, bridging a once-formidable gap in our knowledge of how to recapture vigor from what was once considered irreversible cellular senescence. The promise is vast, and while the ultimate applications remain an open horizon, the path ahead is fueled by these enthralling data that invite us to consider aging not as a closed door, but as a threshold that may be nudged—at least partly—backwards in time.

Subject of Research: Mammalian aging process and cellular senescence

Article Title : Exosomal miR-302b rejuvenates aging mice by reversing the proliferative arrest of senescent cells

News Publication Date : 15 January 2025

Article Doi References : https://doi.org/10.1016/j.cmet.2024.11.013

Image Credits :Scienmag

Keywords : aging senescence exosomes miR-302b cell proliferation rejuvenation lifespan arrest

The centromere’s role in chromosomal integrity is governed by a unique chromatin architecture, primarily characterized by the presence of the histone H3 variant CENP-A. This specialized nucleosome plays an indispensable role in recruiting essential kinetochore proteins such as CENP-C. However, the study delineates a striking decline in CENP-A levels in aging cells, attributed to a p53-dependent pathway. As cells age, they accrue DNA damage, triggering the activation of p53, a key tumor suppressor protein that regulates cell cycle arrest and senescence. In this context, p53 activation exerts a profound inhibitory effect on the transcription and translation of CENP-A and CENP-C, culminating in the inactivation of centromeres.

The researchers meticulously tracked the fate of centromeres across various models of cellular aging, including human fibroblasts obtained from donors spanning a broad age spectrum and chemically induced senescence models. Using high-resolution imaging and RNA sequencing, they demonstrated that the depletion of CENP-A and CENP-C coincides with an accumulation of heterochromatic marks such as H3K9me3, accompanied by a reduction in transcriptionally active marks like H3K4me2. This epigenetic shift effectively silences centromeric transcription, a critical process for de novo CENP-A loading and chromosomal stability.

A pivotal discovery in this study is the role of lysine-specific demethylase 1 (KDM1A/LSD1) in centromeric transcriptional repression. The team uncovered that LSD1 is actively recruited to centromeres in aged cells, mediated by the centromere-binding protein CENP-B. This recruitment leads to the demethylation of H3K4me2, a modification crucial for centromeric RNA transcription. By silencing LSD1 with the small molecule inhibitor 2-PCPA, the researchers succeeded in restoring H3K4me2 levels and reactivating centromeric transcription in aged cells. This intervention also reinstated the expression of CENP-A and mitigated the mitotic defects typically observed in senescent cells.

Further amplifying the study’s significance is the dual inhibition strategy targeting p53 and LSD1. When combined, these interventions not only restored centromeric function but also rejuvenated the cell cycle potential of aged fibroblasts. Mitotic abnormalities, including chromosome missegregation and micronuclei formation, were markedly reduced. Additionally, EdU incorporation assays revealed a significant improvement in the proliferative capacity of aged cells subjected to this dual inhibition. These findings underscore the potential for targeted epigenetic therapies to counteract cellular senescence and enhance genome stability in aging cells.

Human tissue samples, including those from the lung and kidney, corroborated these findings, revealing consistent downregulation of centromeric transcripts and CENP-A levels with advancing age. Notably, variations in centromeric activity were observed across tissue types, reflecting the heterogeneity of the aging process. The study also extended its analysis to murine models, demonstrating that the decline in centromeric protein expression and transcriptional activity is a conserved feature of aging across species.

This research not only elucidates a novel epigenetic mechanism underlying centromeric inactivation but also opens avenues for therapeutic exploration. By targeting LSD1 and p53, it may be possible to develop interventions that restore chromosomal integrity and mitigate age-related cellular dysfunction. The implications of this work extend beyond fundamental biology, offering potential applications in addressing age-related pathologies and enhancing tissue regeneration.

The findings presented in this study are poised to redefine our understanding of aging at the chromosomal level. The strategic restoration of centromeric function presents a promising frontier in the pursuit of longevity and improved cellular health. As the research community delves deeper into the molecular intricacies of aging, these revelations underscore the transformative potential of precision epigenetics in combating the deleterious effects of aging.

Subject of Research: Centromere inactivation and reactivation mechanisms in human aging cells
Article Title: Centromere inactivation during aging can be rescued in human cells
News Publication Date: 2025
Article Doi References: [GSE250322](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE250322)
Image Credits: Not provided
Keywords: centromere, aging, epigenetics, CENP-A, CENP-C, p53, LSD1, chromatin, genome stability, cellular senescence

The decline of Nicotinamide Adenine Dinucleotide (NAD+) levels in the body is intrinsically linked to aging, manifesting in reduced mitochondrial energy production, oxidative stress, DNA damage, and cognitive impairments. NMN, a precursor to NAD+, has shown the potential to mitigate these age-related complications by replenishing NAD+ levels. Preclinical studies and animal models have demonstrated NMN’s efficacy in combating conditions such as Alzheimer’s disease, type 2 diabetes, obesity, and cardiovascular diseases. Despite these encouraging findings, the dearth of long-term clinical safety data raises critical questions about the widespread use of NMN as a health supplement.

Scientific investigations have identified NMN as a bioactive nucleotide formed from nicotinamide and ribose, naturally occurring in certain fruits, vegetables, and meats. NMN’s role in NAD+ biosynthesis positions it as a vital compound in cellular energy metabolism and DNA repair. Animal studies have elucidated its ability to enhance mitochondrial function, reduce inflammation, and improve insulin sensitivity. Yet, translating these benefits from animal models to humans remains a significant challenge. Currently, NMN products flood the market, with doses often exceeding 500 mg per day, despite insufficient evidence to substantiate their safety for prolonged use.

Early clinical studies have reported promising results regarding NMN’s bioavailability and short-term safety. For instance, a study involving healthy men demonstrated that single doses of NMN ranging from 100 to 500 mg were well-tolerated without adverse effects. Similarly, animal studies have revealed NMN’s potential to reverse age-related vascular dysfunction, cognitive decline, and metabolic disorders. However, these findings are tempered by concerns over high-dose administration and long-term implications. The toxicological profile of NMN in humans remains underexplored, necessitating extensive clinical trials to establish safe dosage thresholds and understand potential risks.

The burgeoning NMN market underscores a critical gap in regulatory oversight. As manufacturers capitalize on the anti-aging hype, the absence of stringent approval processes exposes consumers to unverified claims. Unlike heavily regulated pharmaceutical drugs, NMN supplements often bypass rigorous safety evaluations, being marketed as functional foods. This regulatory void has prompted calls for stricter standards to ensure the safety and efficacy of NMN products.

Beyond its anti-aging promises, NMN’s therapeutic potential spans a wide array of conditions. Research highlights its role in mitigating Alzheimer’s pathology, restoring mitochondrial bioenergetics, and reducing oxidative stress. NMN supplementation has also shown promise in addressing reproductive aging, enhancing oocyte quality, and supporting embryonic development in aged animal models. Despite these advances, the lack of longitudinal human studies raises concerns about potential side effects. Prolonged NAD+ upregulation, for instance, may exacerbate certain aging-related phenotypes, underscoring the need for a balanced approach to supplementation.

Emerging evidence suggests that NMN’s effectiveness is mediated through its impact on sirtuin activity, mitochondrial function, and oxidative stress regulation. By boosting NAD+ levels, NMN enhances sirtuin-mediated deacetylation processes, which are crucial for cellular longevity. Furthermore, NMN has been shown to restore mitochondrial communication with the nucleus, a critical factor in maintaining cellular homeostasis. These mechanisms underscore NMN’s potential as a therapeutic agent for age-associated diseases.

While NMN’s pharmacological benefits are promising, its safety profile warrants thorough investigation. Adverse effects associated with other NAD+ precursors, such as Nicotinamide Riboside (NR), highlight the potential risks of excessive NAD+ supplementation. High doses of NR have been linked to liver dysfunction, insulin resistance, and lipid abnormalities. Comparatively, NMN has demonstrated a favorable safety profile in animal studies, but human data is limited. The absence of comprehensive toxicological studies leaves critical gaps in understanding NMN’s long-term implications.

The scientific community’s consensus emphasizes the urgent need for rigorous clinical trials to evaluate NMN’s efficacy and safety. Ongoing studies aim to elucidate its pharmacokinetics, optimal dosages, and potential interactions with existing therapies. The outcomes of these trials will be pivotal in defining NMN’s role in geroscience and its translation into mainstream healthcare.

In conclusion, NMN represents a promising frontier in the pursuit of healthy aging, with its ability to replenish NAD+ levels and mitigate age-related dysfunctions. However, the rapid commercialization of NMN products, coupled with insufficient human safety data, highlights the need for caution. Regulatory frameworks must be strengthened to ensure that NMN supplements meet stringent safety and efficacy standards. Until then, consumers are advised to approach NMN supplementation with informed skepticism, recognizing that the scientific validation of its anti-aging claims is still a work in progress.

Subject of Research: Anti-aging effects and safety of Nicotinamide Mononucleotide (NMN)
Article Title: Nicotinamide mononucleotide (NMN) as an anti-aging health product – Promises and safety concerns
News Publication Date: 2025-01-12
Article Doi References: 10.1016/j.jare.2021.08.003
Image Credits: Not available
Keywords: NMN, anti-aging, NAD+, longevity, mitochondrial function, clinical trials, safety concerns, sirtuins, oxidative stress, regulatory standards

The current investigation into a novel compound, IMD-315, was designed to recalibrate immune response pathways implicated in autoimmune diseases. Yet, the molecular and cellular processes targeted by this agent, including cytokine production and cellular metabolism, are closely tied to the body’s energy balance and heat generation. In many species, females maintain slightly different metabolic and thermal characteristics that may confer certain protective advantages. While this study did not set out to address sex differences in lifespan or the role of body temperature directly, its findings intersect intriguingly with a growing body of literature that posits thermoregulatory efficiency and metabolic adaptability as underlying factors shaping longevity.

The idea that female mammals often outlive their male counterparts has long been attributed to hormonal differences, patterns of oxidative stress, and the influence of sex chromosomes. More recent research points toward a complex interplay of metabolic processes influencing baseline body temperature and energy expenditure. Females, for instance, may benefit from more stable thermal regulatory mechanisms that ensure efficient cellular maintenance and damage repair over the long term. These differences in cellular homeostasis have been tentatively linked to the capacity for fine-tuned immune modulation—an aspect the novel drug candidate aims to replicate pharmacologically.

In the context of IMD-315’s targeted effect on inflammatory pathways, we must consider how inflammation itself is intertwined with metabolic function and thermogenesis. Chronic inflammation can drive metabolic inefficiency, generate excess reactive oxygen species, and disrupt normal cellular repair and renewal processes. By reducing pathological cytokine outputs without broadly suppressing the immune system, this compound demonstrates a principle that nature may have refined through sex-specific evolutionary strategies: keeping inflammatory and metabolic states closely aligned. If females have evolutionarily honed a tighter coupling between their immune networks and metabolic-thermal balance, this could partially explain why their longevity often surpasses that of males.

The “heat of longevity” hypothesis, which remains under active investigation, suggests that lifespan could be influenced by the subtle tuning of body temperature that underlies metabolic and immunological efficiency. IMD-315’s selective kinase targeting and modulation of pro-inflammatory signaling reflect a pharmacological attempt to achieve what might be naturally occurring in more durable organisms or conditions. Females, by possibly operating closer to a metabolic sweet spot, might rely on internal regulatory mechanisms that mirror the drug’s capacity to prevent inflammatory overdrive without compromising essential defenses. Over a lifetime, such equilibrium could reduce the cumulative burden of cellular stress and damage, thus contributing to longevity.

While IMD-315’s primary value lies in its potential therapeutic application for autoimmune and inflammatory disorders, the implications of these findings ripple through broader biological concepts. If this drug succeeds in human trials, its effect may offer clinical confirmation that controlled modulation of immune-metabolic interactions can yield not only immediate symptomatic relief but also potentially influence long-term health outcomes. In doing so, it could provide an experimental framework to examine how small differences in baseline body temperature and metabolic regulation—variables that differ between sexes—impact therapeutic efficacy and disease progression over time.

In practical terms, a future where clinicians can draw on insights like these might allow for more personalized treatments, taking into account factors such as sex, baseline inflammatory profiles, and even subtle variations in metabolic or thermal physiology. This could mean identifying patients who would benefit most from certain immunomodulatory strategies or understanding how restoring thermal-metabolic harmony might slow disease progression. Although the link between body temperature, immune balance, and lifespan is still at the frontier of research, studies like the one emerging from Frontiers in Pharmacology inadvertently push us to think about medical interventions in a more integrated manner.

The sex differences in lifespan and the role of body temperature may still be poorly understood, but their echoes in immunological research underscore a need for more holistic approaches to drug discovery. By paying attention not just to the primary targets of a medication but also to how its mechanism resonates with underlying physiological rhythms—such as metabolic flux, thermoregulation, and cellular maintenance—we might unlock strategies that do more than treat disease. We may also, in time, influence the very parameters that shape how long and how well we live.

Subject of Research

Health

Article Title

The heat of longevity: sex differences in lifespan and body temperature

News Publication Date

Front. Pharmacol., 25 November 2024
Sec. Translational Pharmacology
Volume 15 – 2024
https://doi.org/10.3389/fphar.2024.1512526

Web References

https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1512526/full

References
Ruocco, C., Ragni, M., & Nisoli, E. (2024). The heat of longevity: sex differences in lifespan and body temperature. Frontiers in Pharmacology, 15, 1512526.

A new study published in Nature Communications shows that when a common cell structural protein called filamentous actin, or F-actin, builds up in the brain, it inhibits a key process that removes unnecessary or dysfunctional components within cells, including DNA, lipids, proteins and organelles. The resulting accumulation of waste diminishes neuronal functions and contributes to cognitive decline. By tweaking a few specific genes in aging fruit flies’ neurons, the researchers prevented F-actin buildup, maintained cellular recycling and extended the healthy lifespan of fruit flies by approximately 30%.

Actin, a family of proteins that help give cells their shape, are abundant throughout the body. F-actin forms filaments that are essential for maintaining cell structure and many other functions. The researchers, led by former postdoctoral scholar Edward (Ted) Schmid in David Walker’s lab, noticed F-actin buildup in the brains of aging fruit flies and wondered if it contributed to brain aging and overall loss of organismal health.

Their first clue of a correlation: Flies on a restricted diet both lived longer and had less F-actin buildup in their brains. Their second clue: When treated with a drug known to extend lifespan, called rapamycin, there was also less F-actin in the brains of aged flies.

“But that’s correlation, not a direct demonstration that F-actin is detrimental to aging of the brain,” said Walker, senior author and UCLA professor of integrative biology and physiology. “To get at causality, we turned to genetics.”

Because the fruit fly genome is thoroughly mapped and understood, the group was able to target in aging fruit flies genes that are known to play important roles in the accumulation of actin filaments. That included a gene called Fhos, a member of a family of proteins known to elongate and organize actin filaments.

“When we reduced Fhos expression in aging neurons, it prevented the accumulation of F-actin in the brain,” said Schmid, now an investigator at the Arkansas Biosciences Institute and assistant professor at Arkansas State University. “This really allowed us to expand our study because now, we had a direct way to target F-actin accumulation in the brain and study how it affects the aging process.”

Even though the genetic intervention was targeted to just neurons, it improved the flies’ overall health. They lived 25-30% longer, while showing signs of improved brain function as well as markers of improved health in other organ systems. Preventing F-actin accumulation protected cognitive function, which shows the buildup is driving age-onset cognitive decline.

“Flies get more forgetful as they age, and their ability to learn and remember declines in middle age, just like it does in people,” Walker said. “If we prevent accumulation of F-actin, it helps the flies learn and remember when older — which tells us the buildup is not benign.”

Further investigation showed the F-actin was interfering with the body’s “cellular garbage disposal system.” Damaged or superfluous proteins and other components inside a cell are broken down in a process called “autophagy.” Aging research has established that autophagy pathways become less active with age, but no one knew exactly why.

The new study shows that preventing F-actin accumulation led to much more active autophagy in the brains of aged fruit flies. The authors found that if they removed F-actin but also disabled autophagy, it did not slow aging: The primary mechanism by which F-actin drives brain aging appears to be by impairing autophagy. The researchers also showed that disrupting F-actin in aged brains can restore brain autophagy to youthful levels and reverse certain cellular makers of brain aging.

These findings may be good news for the elderly fruit flies with reduced F-actin in their brains. But it has not yet been demonstrated in humans, and developing interventions to prevent F-actin accumulation might prove more challenging. Still, the discovery directs researchers in a fruitful new direction for healthier aging in people.

“Most of us in the aging field are focused on moving beyond lifespan into what we call the healthspan,” said Walker. “We want to help people enjoy good health and a high quality of life while extending the lifespan. Our study improved cognitive and gut function, activity level, and overall healthspan of fruit flies — and offers hope for what we might be able to achieve in humans.”

The research was funded by the National Institutes of Health’s National Institute on Aging.